Daniel Langlois, DVM, DACVM, is a veterinary clinician scientist with specialty training and board certification in small animal internal medicine. His research program is primarily focused on copper-associated diseases and therapeutic targeting of copper in dogs.

Pathologic hepatic copper accumulation has become an epidemic in recent years. While the exact etiology remains unknown, it is likely that large amounts of dietary copper in commercial dog foods have exacerbated underlying genetic susceptibilities to copper overload. Despite wide-spread recognition of copper-induced liver disease in dogs, there have been relatively few advances in diagnostic testing and treatment options in recent years. Dr. Langlois and his team are actively working to develop minimally invasive biomarkers and new treatment approaches for this potentially fatal disease. Work in this field also has led the team to more broadly investigate applications of copper chelating agents, especially as it relates to cancer treatment across multiple species.

In addition to his copper-related work, Dr. Langlois has long-standing interests in clinical endocrinology, specifically adrenal gland disorders. Disease resulting from both hyper- and hypo-functioning adrenal glands are far more common in dogs than in humans. The diagnosis and treatment of these conditions can be challenging and of substantial cost to pet owners. The Langlois team is currently investigating new diagnostic testing options and refined treatment protocols to help address these limitations.